Premium
Contrast‐enhanced MR imaging of the liver
Author(s) -
Runge Val M.,
Rijcken Tammo H. Pels,
Davidoff Ashley,
Wells John W.,
Stark RT David D.
Publication year - 1994
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880040311
Subject(s) - gadolinium , gadodiamide , medicine , lesion , nuclear medicine , magnetic resonance imaging , radiology , gadoxetic acid , chelation , nephrogenic systemic fibrosis , pathology , chemistry , gadolinium dtpa , organic chemistry
Postcontrast images with a 0.1 mmol/kg dose of a gadolinium chelate with extracellular distribution, when acquired dynamically during breath holding, can improve both differential diagnosis and lesion recognition in liver MR imaging. Initial results at 0.3 mmol/kg, compared with 0.1 mmol/kg, suggest a substantial improvement in lesion identification at the high dose, as assessed by using signal intensity difference divided by noise. Of the gadolinium chelates with predominantly renal excretion, only gadoteridol is presently approved in the United States at the high dose, with limited clinical evaluation for liver imaging performed to date. For linear chelates, such as gadopentetate dimeglumine and gadodiamide injection, the degree to which release of free gadolinium ion occurs is a possible issue because of lower in vivo stability (42,43). Preliminary results with hepatobiliary gadolinium chelates and iron particulate agents are favorable with regard to efficacy, although these agents remain in clinical trials.